Literature DB >> 7239130

Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat.

J Stachura, A Tarnawski, K J Ivey, T Mach, J Bogdal, J Szczudrawa, B klimczyk.   

Abstract

We studied whether 16,16--dimethyl prostaglandin E2 (dmPGE2) may prevent acute liver damage induced by carbon tetrachloride (CCl4) in the rat. One hundred thirty male rats were divided into the following groups: (1) controls, (2) rats given CCl4 6670 mg/kg body wt subcutaneously, (3) rats pretreated with 5 micrograms/kg dmPGE2 given subcutaneously 30 min before, and 8 and 24 h after CCl4 administration, and (4) animals given dmPGE2 only as in group 3. Liver damage was assessed by biochemical studies (SGPT, serum alkaline phosphatase, and bilirubin) and by histology. In rats receiving CCl4 alone, SGPT activities were significantly elevated to 1024 +/- 82 U/L, 1270 +/- 120 U/L, 386 +/- 48 U/L and 208 +/- 20 U/L at 24, 48, 96, and 120 h after CCl4 respectively. In animals pretreated with dmPGE2 before CCl4, SGPT activities were 201 +/- 24 U/L, 55 +/- 4.6 U/L, 28 +/- 4 U/L, and 24 +/- 4 U/L at 24, 48, 96, and 120 h after CCl4, respectively (p less than 0.01, versus animals receiving CCl4 only). Histologically, livers of rats treated with CCl4 alone showed severe centrilobular necrosis at 24 and 48 h. Livers of animals pretreated with dmPGE2 before CCl4 did not show necrosis. It is concluded that dmPGE2 protects the liver against cell necrosis induced by CCl4 in the rat.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7239130

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

1.  Beneficial effects of administering intraportal prostaglandin E1 postoperatively to hepatectomy patients with massive intraoperative blood loss.

Authors:  T Katsuramaki; M Mukaiya; K Yamashiro; H Kimura; R Denno; K Hirata
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  Arachidonic acid metabolites in carbon tetrachloride-induced liver injury.

Authors:  N Kawada; Y Mizoguchi; K Kobayashi; S Yamamoto; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1990-06

3.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

4.  The effects of intraportal prostaglandin E1 administration on hepatic warm ischemia and reperfusion injury in dogs.

Authors:  E Totsuka; M Sasaki; K Takahashi; Y Toyoki; K Seino; S Chiba; S Narumi; K Hakamada; T Morita; M Konn
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

5.  Protective effects of endothelin-1 on acute pancreatitis in rats.

Authors:  M Kogire; K Inoue; S Higashide; K Takaori; Y Echigo; Y J Gu; S Sumi; K Uchida; M Imamura
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

6.  Misoprostol protection against acetaminophen-induced hepatotoxicity in the rat.

Authors:  S P Lim; F J Andrews; P E O'Brien
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

7.  Arachidonate metabolism in D-galactosamine or carbon tetrachloride-induced acute and chronic liver injuries in rats.

Authors:  P Liu; N Kawada; Y Mizoguchi; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1992-10

8.  Preventative effect of PGE1 for postoperative liver damage.

Authors:  N Iwatsuki; A Yasuda; S Tokutomi; T Saishu; Y Koga; Y Hashimoto
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

9.  Effect of prostaglandins and superoxide dismutase administration on oxygen free radical production in experimental acute pancreatitis.

Authors:  D Closa; O Bulbena; J Rosello-Catafau; L Fernandez-Cruz; E Gelpi
Journal:  Inflammation       Date:  1993-10       Impact factor: 4.092

Review 10.  Severe acute hepatitis A associated with acute pure red cell aplasia.

Authors:  S Tomida; Y Matsuzaki; M Nishi; T Ikegami; T Chiba; M Abei; N Tanaka; T Osuga; Y Sato; T Abe
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.